A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101). Article

Porter, Alyx B, Liu, Heshan, Kohli, Sadhna et al. (2020). A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101). . JOURNAL OF CLINICAL ONCOLOGY, 38(15_suppl), 12007-12007. 10.1200/jco.2020.38.15_suppl.12007

cited authors

  • Porter, Alyx B; Liu, Heshan; Kohli, Sadhna; Cerhan, Jane H; Sloan, Jeff A; McMurray, Ryan; Le-Rademacher, Jennifer; Loprinzi, Charles L; Villano, John L; Kizilbash, Sani Haider; Mehta, Minesh P; Jaeckle, Kurt A; Brown, Paul D

authors

publication date

  • May 20, 2020

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Neurosciences
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 12007

end page

  • 12007

volume

  • 38

issue

  • 15_suppl